Against this backdrop, small-molecule agonists and inhibitors of MTFP1, as well as RNA interference and gene-editing tools, have demonstrated potential in animal studies to improve metabolic disorders and suppress tumor progression. This evidence concerns the gene MTFP1 and metabolic disease.